Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICAFUNGIN IN SODIUM CHLORIDE 0.9% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses,Treatment of esophageal candidiasis,Prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
100 mg intravenously once daily for invasive candidiasis; 150 mg intravenously once daily for esophageal candidiasis.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is approximately 13-20 hours in adults; supports once-daily dosing. Half-life is prolonged in moderate-to-severe hepatic impairment (Child-Pugh B/C) but no dosage adjustment is required.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Micafungin is metabolized by arylsulfatase and catechol-O-methyltransferase (COMT) to the M1 metabolite, and further metabolized by CYP3A4 to M2; however, CYP3A4 plays a minor role. The drug is not a significant inhibitor or inducer of CYP enzymes.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily biliary/fecal (≈71% of administered dose recovered in feces as parent drug and metabolites); renal excretion accounts for ≈15% (urine: <1% as unchanged drug).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Highly protein-bound (≥99.8%), primarily to albumin; slight binding to α1-acid glycoprotein.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Volume of distribution at steady state (Vss) is approximately 0.2-0.3 L/kg in adults; indicates limited tissue distribution, primarily confined to plasma and interstitial fluid.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Only available as intravenous infusion; oral bioavailability is negligible (<0.1%) due to poor gastrointestinal absorption.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No dosage adjustment required for any degree of renal impairment.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
In moderate hepatic impairment (Child-Pugh B), reduce dose to 100 mg once daily; no data for severe impairment (Child-Pugh C). No adjustment for mild impairment.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
For invasive candidiasis: 2 mg/kg (max 100 mg) intravenously once daily for patients ≥40 kg; 2 mg/kg once daily for patients <40 kg. For esophageal candidiasis: 3 mg/kg (max 150 mg) once daily.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
No specific dose adjustment; use standard adult dosing based on renal and hepatic function.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
There is no FDA black box warning for micafungin.
None.
Hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions,Hepatic effects: elevations in liver enzymes, bilirubin, and rare cases of hepatic necrosis or hepatitis,Renal effects: elevations in serum creatinine and BUN,Hematologic effects: hemolytic anemia, leukopenia, thrombocytopenia,Injection site reactions: phlebitis, thrombophlebitis,Photosensitivity and risk of skin malignancies in patients with prolonged exposure
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to micafungin or any component of the formulation
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No known food interactions. Grapefruit and grapefruit juice do not interact with micafungin.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Micafungin is classified as FDA Pregnancy Category C. In animal studies, embryotoxicity and skeletal abnormalities were observed at doses 0.04 times the human dose. No adequate human studies exist. First trimester: Theoretical risk based on animal data; use only if benefit justifies risk. Second/third trimester: Limited data; may be used if clearly needed due to lack of alternative therapy.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Unknown if micafungin is excreted in human milk. Due to high molecular weight (ca. 1292 Da) and high protein binding (>99%), excretion is likely minimal. M/P ratio not determined. Caution advised; consider alternative therapy or temporarily discontinue breastfeeding during infusion.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy-induced physiological changes (increased plasma volume, enhanced renal clearance) may alter pharmacokinetics. However, specific dose adjustment guidelines are unavailable. Standard adult dosing (100-200 mg/day for invasive candidiasis) is typically used; monitor clinical response and serum drug levels if available.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Micafungin is an echinocandin antifungal that inhibits beta-(1,3)-D-glucan synthase. Administer IV only; do not bolus. Monitor hepatic function due to risk of elevated transaminases. Caution in patients with moderate to severe hepatic impairment (Child-Pugh B/C). Use with caution in patients with hypersensitivity to other echinocandins. May increase sirolimus and nifedipine levels; monitor levels. No renal dose adjustment needed. Do not mix with other drugs in same infusion line.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously to treat serious fungal infections.,Report any signs of allergic reaction: rash, itching, difficulty breathing, swelling of face or throat.,Monitor for symptoms of liver problems: jaundice, dark urine, abdominal pain, unexplained fatigue.,Inform your doctor about all medications you take, including over-the-counter drugs and supplements.,You may have blood tests to monitor liver function during treatment.,Do not drive or operate heavy machinery if you experience dizziness or confusion.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Micafungin, an echinocandin antifungal, inhibits CYP3A4 and P-glycoprotein, thereby decreasing the hepatic and intestinal metabolism of Lercanidipine, a CYP3A4 substrate. This leads to increased plasma concentrations of Lercanidipine, potentially causing excessive vasodilation, hypotension, reflex tachycardia, and peripheral edema. In severe cases, this interaction may precipitate syncope, myocardial ischemia, or acute kidney injury due to hypoperfusion."
"Rifapentine, a potent inducer of hepatic CYP450 enzymes and drug transporters, paradoxically increases serum concentrations of micafungin, an echinocandin antifungal. This interaction is thought to occur via inhibition of micafungin's biliary excretion and possibly through competitive binding to plasma proteins, leading to reduced clearance and elevated trough levels. Clinically, this may increase the risk of micafungin-related hepatotoxicity and requires close monitoring of liver function and therapeutic drug monitoring if available."
"Micafungin, a potent inhibitor of CYP3A4 and a substrate of CYP3A4, may reduce the hepatic clearance of Perhexiline, a CYP3A4 substrate with a narrow therapeutic index. Co-administration can result in elevated serum concentrations of Perhexiline, increasing the risk of hepatotoxicity and peripheral neuropathy. This interaction is significant as it may lead to adverse outcomes including liver injury and neurological deficits."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICAFUNGIN IN SODIUM CHLORIDE 0.9% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
MICAFUNGIN IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICAFUNGIN IN SODIUM CHLORIDE 0.9% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICAFUNGIN IN SODIUM CHLORIDE 0.9% is: 100 mg intravenously once daily for invasive candidiasis; 150 mg intravenously once daily for esophageal candidiasis.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICAFUNGIN IN SODIUM CHLORIDE 0.9% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICAFUNGIN IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Micafungin is classified as FDA Pregnancy Category C. In animal studies, embryotoxicity and skeletal abnormalities were observed at doses 0.04 times the human dose. No adequate hum. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.